Skip to main content
Equibles

UBS Group AG

Position in LXEO — Lexeo Therapeutics, Inc.

CIK 1610520 ZURICH, V8
Back to LXEO Full portfolio

Position in LXEO

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$1,648,074
-$198,695 QoQ
Shares Held
354,044
+10.0% QoQ
Ownership
0.432%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 141 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in LXEO Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,801 across 560 Biotechnology names. LXEO ranks #225 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in LXEO

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,648,074 354,044
2026-03-31 $1,846,769 321,737
2025-12-31 $2,791,153 281,083
2025-09-30 $1,659,395 249,909
2025-06-30 $1,093,053 271,904
2025-03-31 $111,324 32,082
2024-12-31 $335,935 51,054
2024-09-30 $100,452 11,112
2024-06-30 $50,189 3,129
2024-03-31 $162,554 10,367